195 related articles for article (PubMed ID: 36459284)
1. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Xu B; Sun T; Shi Y; Cui J; Yin Y; Ouyang Q; Liu Q; Zhang Q; Chen Y; Wang S; Wang X; Tong Z; Zhong Y; Wang J; Yan M; Yan X; Wang C; Feng J; Wang X; Hu G; Cheng Y; Ge R; Zhu Z; Zhang W; Shao Z
Breast Cancer Res Treat; 2023 Feb; 197(3):489-501. PubMed ID: 36459284
[TBL] [Abstract][Full Text] [Related]
2. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Friedlander M; Mileshkin L; Lombard J; Frentzas S; Gao B; Wilson M; Meniawy T; Baron-Hay S; Briscoe K; McCarthy N; Fountzilas C; Cervantes A; Ge R; Wu J; Spira A
Br J Cancer; 2023 Sep; 129(5):797-810. PubMed ID: 37474720
[TBL] [Abstract][Full Text] [Related]
3. Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
Wu X; Zhu J; Wang J; Lin Z; Yin R; Sun W; Zhou Q; Zhang S; Wang D; Shi H; Gao Y; Huang Y; Li G; Wang X; Cheng Y; Lou G; Gao Q; Wang L; Du X; Pan M; Mu X; Li L; Li M; Mu S; Kong B
Clin Cancer Res; 2022 Feb; 28(4):653-661. PubMed ID: 34844979
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).
Kim SH; Im SA; Suh KJ; Lee KH; Kim MH; Sohn J; Park YH; Kim JY; Jeong JH; Lee KE; Choi IS; Park KH; Kim HJ; Cho EK; Park SY; Kim M; Kim JH
Eur J Cancer; 2023 Dec; 195():113386. PubMed ID: 37890351
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
Kotani H; Masuda N; Yamashita T; Naito Y; Taira T; Inoue K; Takahashi M; Yonemori K; Toyoizumi S; Mori Y; Nagasawa T; Hori N; Iwata H
Breast Cancer; 2022 Nov; 29(6):1088-1098. PubMed ID: 35907135
[TBL] [Abstract][Full Text] [Related]
6. Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
Lee KH; Sohn J; Goodwin A; Usari T; Lanzalone S; Im SA; Kim SB
Cancer Res Treat; 2021 Oct; 53(4):1084-1095. PubMed ID: 33781053
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline
Ayoub JP; Wildiers H; Friedlander M; Arun BK; Han HS; Puhalla S; Shparyk Y; Jakobsen EH; Wu M; Bach BA; Feng D; Ratajczak CK; Maag D; Diéras V
Ther Adv Med Oncol; 2021; 13():17588359211059601. PubMed ID: 34917174
[TBL] [Abstract][Full Text] [Related]
8. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S; O'Sullivan CC; Elkhanany A; Anderson IC; Barve M; Blau S; Cherian MA; Peguero JA; Goetz MP; Plourde PV; Portman DJ; Moore HCF
Ann Oncol; 2023 Dec; 34(12):1131-1140. PubMed ID: 38072513
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Wardley A; Cortes J; Provencher L; Miller K; Chien AJ; Rugo HS; Steinberg J; Sugg J; Tudor IC; Huizing M; Young R; Abramson V; Bose R; Hart L; Chan S; Cameron D; Wright GS; Graas MP; Neven P; Rocca A; Russo S; Krop IE
Breast Cancer Res Treat; 2021 May; 187(1):155-165. PubMed ID: 33591468
[TBL] [Abstract][Full Text] [Related]
10. Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.
Xu B; Yin Y; Dong M; Song Y; Li W; Huang X; Wang T; He J; Mu X; Li L; Mu S; Zhang W; Li M
Cancer Med; 2021 Jan; 10(1):109-118. PubMed ID: 33128299
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
[TBL] [Abstract][Full Text] [Related]
12. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
15. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK
Lancet Oncol; 2020 Oct; 21(10):1269-1282. PubMed ID: 32861273
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
Xu J; Keenan TE; Overmoyer B; Tung NM; Gelman RS; Habin K; Garber JE; Ellisen LW; Winer EP; Goss PE; Yeap BY; Chabner BA; Isakoff SJ
Breast Cancer Res Treat; 2021 Oct; 189(3):641-651. PubMed ID: 34417675
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Fasching PA; Link T; Hauke J; Seither F; Jackisch C; Klare P; Schmatloch S; Hanusch C; Huober J; Stefek A; Seiler S; Schmitt WD; Uleer C; Doering G; Rhiem K; Schneeweiss A; Engels K; Denkert C; Schmutzler RK; Hahnen E; Untch M; Burchardi N; Blohmer JU; Loibl S;
Ann Oncol; 2021 Jan; 32(1):49-57. PubMed ID: 33098995
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
